- Company
- HK Inno.N releases its GERD drug K-CAB in Singapore
- by Chon, Seung-Hyun Sep 5, 2023 05:40am
- On the 4th, HK Inno.N announced that it had officially released its novel gastroesophageal reflux disease (GERD) treatment K-CAB in Singapore. HK Inno.N held a symposium to celebrate K-CAB’s launch at the Conrad Centennial Singapore Hotel on August 31st. K-CAB was approved in February in Singapore under the same brand name, K-CAB.
- Policy
- Drug crime regulation,
- by Lee, Jeong-Hwan Sep 5, 2023 05:40am
- It is expected that a bill that would impose an obligation on doctors and pharmacists who prescribe and dispense drugs with a risk of misuse, such as narcotics, to check medication history through the Drug Safety Information System (DUR) will quickly pass the National Assembly. This is because a large number of drug-related crimes have occur
- Policy
- Why many choline alfoscerates accepted price cuts
- by Lee, Tak-Sun Sep 5, 2023 05:39am
- Companies are reluctant to self-manufacture their brain function enhancer choline alfoscerates despite price cuts. Only 20% of the companies decided to protect their drug price by switching to self-manufacture, and the prices of the others that opted to continue manufacturing through contract manufacture organizations (CMOs) were cut.
- Company
- Humira market biosimilar share
- by Kim, Jin-Gu Sep 4, 2023 05:04am
- Two years have passed since the biosimilar of the autoimmune disease treatment Humira was launched in the domestic market, and its share in the adalimumab market was found to be around 14%. According to IQVIA, a pharmaceutical market research firm, on the 2nd, the market for 'Adalimumab' ingredients in the first half of this year was 50.1 billio
- Company
- Will Phesgo be listed with pricing premiums as a biobetter?
- by Eo, Yun-Ho Sep 4, 2023 05:04am
- Whether another biobetter after Nexviazyme will be receiving premium pricing in Korea is gaining attention. According to industry sources on the 30th, Roche Korea’s subcutaneous fixed-dose combination injection Phesgo (pertuzumab, trastuzumab) that combined ‘Perjeta’ and ‘Herceptin’ has passed the Health Insurance Review and Assess
- Policy
- New GLP-1 RA stops reimb discussions in KOR
- by Lee, Tak-Sun Sep 4, 2023 05:04am
- The debut of a new GLP-1 analog used as an adjuvant to dietary and exercise therapy in diabetes patients has been postponed in Korea. This comes as a disappointment as only one single-agent drug is currently reimbursed in Korea, and the high global demand for the drugs has rendered domestic supply short. According to the Health Insur
- Opinion
- [Reporter’s View] Disclose PVA results in advance as well
- by Lee, Tak-Sun Sep 4, 2023 05:04am
- The government announced the 7,000 drug items whose insurance price ceiling will be lowered according to the reevaluations that were conducted in advance. This preemptive measure was made out of concern over the large settlement of price differences and returns that may occur with the price adjustment. The product list and upper limit pr
- Company
- Can Koselugo pass the Pharmaceutical Evaluation Committee?
- by Eo, Yun-Ho Sep 4, 2023 05:04am
- Koselugo, a new drug for pediatric neurofibroma, is once again awaiting discussion for listing on insurance benefits. Attention is focused on whether AstraZeneca Korea's neurofibromatosis new drug Koselugo, which was decided for re-discussion at HIRA last month, will be presented to the committee on the 7th. Koselugo failed to reach an agree
- Company
- Enhertu posts KRW 7.4 bil in H1 sales without reimb
- by Kim, Jin-Gu Sep 1, 2023 05:44am
- Daiichi Sankyo Korea’s HER2-positive breast cancer treatment ‘Enhertu (trastuzumab deruxteca); has raised sales of over KRW 7 billion in H1 this year without reimbursement. According to the market research institution IQVIA on the 31st, Enhertu posted sales of KRW 7.4 billion in H1 this year, making KRW 2.2 billion in Q1 and KRW 5.2 bi
- Policy
- Kanoa, the upper limit price was reduced further by PVA
- by Lee, Tak-Sun Sep 1, 2023 05:44am
- It was found that the upper limit of the choline alposerate formulation Kanoa Soft Cap sold by Ahnook Pharm has been reduced more with PVA (use-drug linkage agent) than the Kanoa Soft Capre-evaluation of the upper limit. There are a total of 18 items that have been re-evaluated and reduced by both the PVA this time, and among them, Kanoa
